Sleeper Diseases: Forecast and Assessment of Neglected Disease Market Opportunities

Sleeper Diseases: Forecast and Assessment of Neglected Disease Market Opportunities published by Insight Pharma Reports in February, 2006. This report price starts from US $ 2100.

Introduction

Sleeper diseases comprise a broad spectrum of increasingly recognized conditions with various degrees of neuropsychiatric involvement. Many of these conditions are now clearly defined, earning them increasing acceptance as real disorders that can and should be addressed by pharmacotherapy.

Several of these emerging sleeper diseases share key properties that make them highly interesting for the pharmaceutical industry:

• They are well defined and "real" beyond any reasonable doubt, although their etiology might be unknown or scientists' understanding of them might be highly incomplete.
• They affect a considerable number of otherwise healthy individuals in ways that significantly compromise their quality of life, social functioning, and professional accomplishments.
• They respond to treatment with currently available medications (or at least some of their constituent aspects do to a limited degree), and novel drugs (frequently based on genetic insights that reveal possible targets) are being investigated on the basis of scientifically defendable working hypotheses.

In this report, five syndromes the author believes will develop into significant pharmaceutical markets through 2015 have been evaluated.

Table of Contents

• Symptoms, Diagnosis, and Epidemiology
• Etiology
• Inconclusive Results of Genetic Investigations
• Current Drug Treatments and Trials Involving Drugs Approved for Other Indications
  • Anticonvulsants
  • Selective Serotonin Reuptake Inhibitors
  • Atypical Antipsychotics
  • Cholinesterase Inhibitors
  • Antioxidants and Antiexcitatory Drugs
• Potential New Drugs for Autism and Autistic Spectrum Disorders
  • Specific Challenges for Drug Development in Autism
  • Secretin: A Failed Hope
  • CureMark's Digestive Enzymes
  • Oralgam: An Oral Immunoglobulin with Presumed Intestinal Action
  • RG-2077: Another Potential Immunotherapy
  • SRX-251
  • Other Approaches Described in the Patent Literature
• The Autism Drug Therapy Market to 2015
  • A Target Population with a Largely Unpredictable Development
  • Sales Development To Be Driven by New Drugs

References

Index

FIGURES

• Figure 1. Key Symptoms of Autism
• Figure 2. Incidence of U.S. Autism Cases, 1992 to 2003

TABLES

• Table 1. Drugs Approved for Other Indications That Are Used to Manage or Are in Clinical Trials for Autism
• Table 2. Potential New Drugs for Use in Autism

Related Reports